NCT01334112View on ClinicalTrials.gov

Study of Axitinib in Patients With Unresectable Hepatocellular Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 31, 2011

Primary Completion Date

March 31, 2018

Study Completion Date

March 31, 2018

Conditions
Hepatocellular Carcinoma
Interventions
DRUG

Axitinib (AG-013736)

5mg, oral, twice daily, continuous dosing. A dosing cycle is defined as 4 weeks. Treatment may continue until disease progression/relapse

Trial Locations (2)

Unknown

Foothills Hospital, Alberta Health Services, Calgary

University Health Network, Princess Margaret Hospital, Toronto

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

University Health Network, Toronto

OTHER